Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.47%77 Gross-Profit-to-Asset % is 39.26% as of Mar. 2026. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 824 Medical Devices & Instruments companies, Coloplast AS ranks better than 74.51% on this metric.
Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Coloplast AS's annualizedGross Profit for the quarter that ended in Mar. 2026 was $2,918 Mil.
Coloplast AS's average Total Assets over the quarter that ended in Mar. 2026 was $7,433 Mil. Therefore, Coloplast AS's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2026 was 39.26%.
Coloplast AS Gross-Profit-to-Asset % Related Terms
Coloplast AS Gross-Profit-to-Asset % Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Gross-Profit-to-Asset % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBY vs ISRG, BDX, MDLN: Gross-Profit-to-Asset % Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Gross-Profit-to-Asset % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Gross-Profit-to-Asset % distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Gross-Profit-to-Asset % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Gross Profit data used here is four times the quarterly (Mar. 2026) data.
Gross-Profit-to-Asset % is displayed in the 30-year financial page.
What does a Gross-Profit-to-Asset % of 39.26% mean?
Coloplast AS (CLPBY) has a Gross-Profit-to-Asset % of 39.26% as of Mar. 2026. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #210 out of 824 companies in the Medical Devices & Instruments industry, placing it in the top 25.5%.
Is Coloplast AS's Gross-Profit-to-Asset % too high?
Coloplast AS's current Gross-Profit-to-Asset % is 39.26%. The Medical Devices & Instruments industry median Gross-Profit-to-Asset % is 24.03. Coloplast AS's value of 39.26% is 63.4% above this industry median. Based on the distribution chart, Coloplast AS ranks #210 out of 824 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Gross-Profit-to-Asset % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #210 out of 824 companies for Gross-Profit-to-Asset %. This puts Coloplast AS in the upper half of its industry. The industry median Gross-Profit-to-Asset % is 24.03. Coloplast AS's value of 39.26% is 63.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross-Profit-to-Asset % for a Medical Devices & Instruments company?
The median Gross-Profit-to-Asset % among Medical Devices & Instruments companies is 24.03, based on 824 companies in the industry. Companies in the top quartile (top 25%) have a Gross-Profit-to-Asset % significantly above this median, while those in the bottom quartile fall well below. However, Gross-Profit-to-Asset % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Gross-Profit-to-Asset % of 39.26% is 63.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross-Profit-to-Asset % mean?
A high Gross-Profit-to-Asset % can signal that a stock is expensive relative to its fundamentals. Gross Profit to Asset Ratio is the total gross profit divided by total assets. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median Gross-Profit-to-Asset % is 24.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Gross-Profit-to-Asset % is 39.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.70 — trading 48.7% below its estimated fair value. The current Gross-Profit-to-Asset % is 39.26% and 63.4% above the Medical Devices & Instruments industry median of 24.03. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross-Profit-to-Asset % calculated?
Gross-Profit-to-Asset % is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Gross-Profit-to-Asset % is 39.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.70 is trading 48.7% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Gross-Profit-to-Asset %: 39.26%
GF Value™: $13.05 vs. price of $6.70 (48.7% below fair value)
Industry Position: 63.4% above the Medical Devices & Instruments median (#210 of 824)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Gross-Profit-to-Asset % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
